Treatment of Benign Prostatic Hyperplasia

被引：26

作者：

Pinheiro, Luis Campos ^{[1
]}

Pisco, Joao Martins ^{[1
]}

机构：

[1] St Louis Hosp, Dept Intervent Radiol, Rua Luz Soriano 182, P-1200249 Lisbon, Portugal

来源：

TECHNIQUES IN VASCULAR AND INTERVENTIONAL RADIOLOGY | 2012年 / 15卷 / 04期

关键词：

benign prostatic hyperplasia; BPH medical treatment; BPH surgery; BPH minimal invasive treatments;

D O I：

10.1053/j.tvir.2012.09.004

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Lower urinary tract symptoms (LUTS) may be a sign of aging rather than a consequence of benign prostatic enlargement (BPE) or benign prostatic obstruction (BPO). Medical or invasive treatments should address the bothersome symptoms and the quality of life of patients. Alpha blockers and 5 -alpha reductase inhibitors are most frequently used in benign prostatic hyperplasia (BPH) medical treatments, whereas Transurethral Resection of the Prostate (TURP) remains the "gold standard" for surgical treatments. Several minimal invasive treatments are emerging with promising outcomes. (C) 2012 Published by Elsevier Inc.

引用

页码：256 / 260

页数：5

共 30 条

[11] The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
McConnell, JD
Roehrborn, CG
Bautista, OM
Andriole, GL
Dixon, CM
Kusek, JW
Lepor, H
McVary, KT
Nyberg, LM
Clarke, HS
Crawford, ED
Diokno, A
Foley, JP
Foster, HE
Jacobs, SC
Kaplan, SA
Kreder, KJ
Lieber, MM
Lucia, MS
Miller, GJ
Menon, M
Milam, DF
Ramsdell, JW
Schenkman, NS
Slawin, KM
Smith, JA
Kusek, JW
Nyberg, LM
Briggs, JP
McConnell, JD
Crawford, ED
Homan, K
Donohue, R
Parker, D
Easterday, K
Robertson, K
Kaplan, S
Wentland, M
Hardy, L
Roehrborn, C
Ahrens, A
McConnell, J
Hall, D
Cutts, D
Carter, S
Waldrep, K
Schenkman, N
Sanetrik, K
Sihelnik, S
Zorn, B
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (25) : 2387 - 2398
[12] Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men
Meigs, JB
Mohr, B
Barry, MJ
Collins, MM
McKinlay, JB
[J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2001, 54 (09) : 935 - 944
[13] Mishriki SF, 2008, UROLOGY, V72, P322, DOI 10.1016/j.urology.2008.01.081
[14] Benign prostatic hyperplasia: dietary and metabolic risk factors
Nandeesha, H.
[J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2008, 40 (03) : 649 - 656
[15] Correlation between the international prostatic symptom score and a pressure-flow study in the evaluation of symptomatic benign prostatic hyperplasia
Netto, NR
DAncona, CAL
deLima, ML
[J]. JOURNAL OF UROLOGY, 1996, 155 (01) : 200 - 202
[16] IDENTIFICATION, QUANTIFICATION, AND LOCALIZATION OF MESSENGER-RNA FOR 3 DISTINCT ALPHA1 ADRENERGIC-RECEPTOR SUBTYPES IN HUMAN PROSTATE
PRICE, DT
SCHWINN, DA
LOMASNEY, JW
ALLEN, LF
CARON, MG
LEFKOWITZ, RJ
[J]. JOURNAL OF UROLOGY, 1993, 150 (02) : 546 - 551
[17] High power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients
Reich, O
Bachmann, A
Siebels, M
Hofstetter, A
Stief, CG
Sulser, T
[J]. JOURNAL OF UROLOGY, 2005, 173 (01) : 158 - 160
[18] Reich O, 2008, J UROLOGY, V180, P246, DOI 10.1016/j.juro.2008.03.058
[19] Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5α-reductase inhibitor dutasteride:: results of 4-year studies
Roehrborn, CG
Lukkarinen, O
Mark, S
Siami, P
Ramsdell, J
Zinner, N
[J]. BJU INTERNATIONAL, 2005, 96 (04) : 572 - 577
[20] Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia
Roehrborn, CG
Marks, LS
Fenter, T
Freedman, S
Tuttle, J
Gittleman, M
Morrill, B
Wolford, ET
[J]. UROLOGY, 2004, 63 (04) : 709 - 715

← 1 2 3 →